AIM ImmunoTech Issues Presentation Detailing Case for Re-Electing Current Directors to Oversee Continued Momentum and Drive Strategy to Create Long-Term Value for Patients and Shareholders

Stock Information for AIM ImmunoTech Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About AIM ImmunoTech Inc.

AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements
AIM ImmunoTech Resumes Trading on NYSE American
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®
AIM ImmunoTech Announces NYSE American Removal of Trading Suspension
AIM ImmunoTech Announces 1-for-100 Reverse Stock Split
AI-Media Redefines Global Accessibility with LEXI Voice at InfoComm 2025
Entertainment Without Borders: AI-Media and Lightning International Join Forces to Make FAST Channels Accessible to Everyone
AI-Media Showcases Translation Innovation with LEXI Voice at KOBA and Broadcast Asia 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.